Advertisement

Isotope Therapy For Bone Metastases

  • Susan E. M. Clarke
Chapter

Abstract

Therapy using radioactive labelled tracer molecules is at present an area of considerable interest and research. The principle of using a tracer molecule to target radiotherapy to a tumour has been well established with the use of iodine-131 in the treatment of follicular thyroid cancer and phosphorus-32 to treat polycythaemia rubra vera (Seidlin et al. 1946; O’Mara 1978).

Keywords

Bone Metastasis Linear Energy Transfer Medullary Thyroid Cancer Follicular Thyroid Cancer Beta Emitter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen SJ, Blake GM, McKeeney DB, Lazarus CR, Blower P, Singh J, Page C, Clarke SEM (1990) Rh-186-v-DMSA: dosimetry of a new radiopharmaceutical for therapy of medullary carcinoma of the thyroid. Nucl Med Commun 11:220–221Google Scholar
  2. Andres R, Blattman H, Pfeiffer G, Schubiger PA, Vogt M, Weinreich R, Wernli C (1986) Radionuclides for therapy: a review. In: Schubiger P, Hasler PH (eds) Radionuclides for therapy. Proceedings of the 4th Bottstein Colloquium. Hoffman la Roche, Basle, pp 9–20Google Scholar
  3. Baulieu JL, Guilloteau D, Baulieu F, Le Floch O, Chambon C, Pourcelot L, Besnard JL (1988) Therapeutic effectiveness of Iodine-131 MIBG for metastases of a non-secreting paraganglioma. J Nucl Med 29:2008–2013PubMedGoogle Scholar
  4. Beer HF, Blauenstein P, Andres R, Hasler PH, Schubiger P (1986) How to get the radionuclide to the right site. In Schubiger P, Hasler PH (eds) Radionuclides for therapy, Proc of 4th Bottstein Colloquium. Hoffman la Roche, Basle, pp 60–74Google Scholar
  5. Blake G (1986) Strontium-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454PubMedGoogle Scholar
  6. Blake GM, Zivanovic MA, Blaquere RM, Fine DR, McEwan EJ, Ackery DM (1988) Sr-89 therapy -measurement of observed dose to skeletal metastases. J Nucl Med 29:549–557PubMedGoogle Scholar
  7. Blower PJ, Clarke SEM, Bisuriadan MM, Singh J, West MJ (1990) Preparation and characterisation of pentavalent Rh-186 DMSA. A possible tumour therapy agent. Nucl Med Commun 11: 212–213CrossRefGoogle Scholar
  8. Boniface G, Izard M, Walker K, McKay D, Sorby P, Harvey Turner J, Morris J (1989) Labelling of monoclonal antibodies with Sm-153 for combined radioimmunoscintigraphy and radioimmunotherapy. J Nucl Med 30:683–691PubMedGoogle Scholar
  9. Bowen BM, Darracott J, Garnett ES, Tomlinson RH (1975) Yttrium-90 citrate colloid for radioisotope synovectomy. Am J Hosp Pharm 32:1027–1030PubMedGoogle Scholar
  10. Carichner S, Eary J, Collins C, Nemiroff K, Richter D, Lewis D, Applebaum F (1989) Samarium-153 EDTMP. Technical aspects of imaging and treatment. Clin Nucl Med 14:B1,11CrossRefGoogle Scholar
  11. Carrelta R, Martin P, Malekian T (1989) Strontium-89 therapy for metastatic prostate and breast carcinoma: a community hospital experience. Clin Nucl Med 14:A5, 11CrossRefGoogle Scholar
  12. Charbord P, L’heritier C, Cukerstein W, Lumbroso J, Tubiana M (1977) Radio-iodine treatment in differentiated thyroid carcinomas. Treatment of first local recurrences and of bone and lung metastases. Ann Radiol 20:783–786PubMedGoogle Scholar
  13. Clarke SEM, Lazarus CR, Edwards S, Murby B, Clarke DG, Roden T, Fogelman I, Maisey MN (1987) Scintigraphy and treatment of MCT with 131I-MIBG. J Nucl Med 28:1820PubMedGoogle Scholar
  14. Dunscombe PB, Ramsey NW (1980) Radioactivity studies on two synovectomy specimens after radiation synovectomy with Yttrium-90-silicate. Ann Rheum Dis 39:87–89PubMedCrossRefGoogle Scholar
  15. Ehrlich P (1906) Collected studies of immunity. John Wiley and Sons, ChichesterGoogle Scholar
  16. Ehrlich P (1960) The collected papers of Paul Ehrlich. Pergamon Press, New York, pp 505–518Google Scholar
  17. Fischer M, Kamanabroo D, Sonderkarys H (1984) Scintigraphic imaging of carcinoid tumours with 131I-MIBG. Lancet ii: 165Google Scholar
  18. Fisher DR (1985) The microdosimetry of monoclonal antibodies labelled with alpha particles. Fourth International Radiopharmaceutical Symposium. CONF -851113, 446–457, Oakridge, TennesseeGoogle Scholar
  19. Francis MD, Slough CL, Tofe AJ (1976) Distribution and effect of P32 EHDP in normal and bone tumour bearing dogs. J Nucl Med 17:548Google Scholar
  20. Goodhead DT (1985) Saturable repair models of radiation action in mammalian cells. Radiat Res 104.S58–S67CrossRefGoogle Scholar
  21. Goodwin D, Meares C, Diamonti C, McCall M, Lai C, Torti F, McTigue M, Martin B (1990) Use of specific antibody for rapid clearance of circulating blood background from tumour imaging proteins. Eur J Nucl Med 9:209–215CrossRefGoogle Scholar
  22. Gorckler WF, Edwards B, Volkert WA (1987) Skeletal localisation of Sm-153 chelates, potential therapeutic bone agents. J Nucl Med 28:495–504Google Scholar
  23. Griffiths MH, York ED, Wessels BW, Denardo GL, Neacy WP (1988) Direct dose confirmation of quantitative autoradiography with micro TLD measurements for radioimmunotherapy. J Nucl Med 29:1795–1809Google Scholar
  24. Hall N, Tokars RP, O’Mara RE (1975) P32 diphosphonate: a potential therapeutic agent. J Nucl Med 16:532Google Scholar
  25. Harvey Turner J, Martindale A, Sorby P, Hetherington E, Fleay R, Hoffman R, Caringbold P (1989) Samarium-153 EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med 15:784–795Google Scholar
  26. Hill JM, Lobe E, Spear RJ (1962) IV colloidal zirconyl phosphate P-32. Clinical studies of over 250 cases. J Nucl Med 3:196Google Scholar
  27. Hisada K, Ando (1973) Radiolanthides as promising tumour scanning agents. J Nucl Med 14:615–617PubMedGoogle Scholar
  28. Hoefnagel CA (1989) The clinical use of 131I metaiodobenzylguanidine for the diagnosis and treatment of neural crest tumours. Academisch Proef SchriftGoogle Scholar
  29. Hoefnagel CA, DeKraker J, Marcuse HR, Voute PA (1986) Detection and treatment of neural crest tumours using 131I-MIBG. In: Schmidt HAE, Ell PJ, Britton KE (eds) Nuklearmedizin -nuclear medicine in research and practice. Schattauer Verlag, Stuttgart, pp 473–476Google Scholar
  30. Hoefnagel CA, Voute PA, DeKraker J, Marcuse HR (1987) Radionuclide diagnosis and therapy of neural crest tumours using iodine-131 MIBG. J Nucl Med 28:308–314PubMedGoogle Scholar
  31. Humm JL, Cobb LM (1990) Non-uniformity of tumour dose in radioimmunotherapy. J Nucl Med 31:75–83PubMedGoogle Scholar
  32. Ketring A (1987) Sm-153-EHDP and rhenium-186 HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum [B] 14:223–232CrossRefGoogle Scholar
  33. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–496PubMedCrossRefGoogle Scholar
  34. Larsen SM, Carrasquillo JA, Krohn KA, Brown JP, McGuffin RW, Ferens JM, Graham MM, Hill LD, Beaumier PL, Helstrom KE, Helstrom I (1983) Localization of 131I labelled P97 specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72:2101–2114CrossRefGoogle Scholar
  35. Lewington VJ, Zivanovic MA, Blake GB, Buchanan RB, Akery DM (1988) Treatment of bone pain in disseminated prostatic cancer using strontium-89. Nucl Med Commun 9:179–186 (abstr)Google Scholar
  36. Marchandise X, Brendel AJ, Caudry M, Charbonnel B, Chatal JF, Lanheche B, Lumsioso J, Marnex R, Schlumberger M, Werneaun JL (1985) Treatment of malignant phaeochromocytomas with 1–131 MIBG. Results of a French multicenter study. Nucl Med 26:51–52Google Scholar
  37. McCardle RJ, Harper P, Spar I, Bale W, Andros G, Jiminez F (1966) Studies with 131I-labeled antibody to human fibrinogen for diagnosis and therapy of tumours. J Nucl Med 7:837–847PubMedGoogle Scholar
  38. McEwan AJ, Catz A, Fields AL, Lewington V, Harbara D, Fine D, Ackery DM (1987) 131I-MIBG in the diagnosis and treatment of carcinoid syndrome. J Nucl Med 28:658Google Scholar
  39. Milstein C (1980) Monoclonal antibodies. Sci Am 243:66–74PubMedCrossRefGoogle Scholar
  40. O’Mara RE (1978) In: RP Spencer (ed) Therapy in nuclear medicine. Grune and Stratton, New York, p 257Google Scholar
  41. Pecker C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Pharmacology, 1:117–139Google Scholar
  42. Peng TX, Moya A, Ayala FJ (1986) Irradiation resistance conferred by super oxide dismutase: possible adaptive role of a natural polymorphism in Drosophila melanogaster. Proc Natl Acad Sci USA 83:684–687PubMedCrossRefGoogle Scholar
  43. Pochin EE (1967). Prospects from the treatment of thyroid carcinoma with radio-iodine. Clin Radiol 18:113–125PubMedCrossRefGoogle Scholar
  44. Pochin EE (1969) Long term hazards of radio-iodine treatment of thyroid carcinoma. In: Hedinger CE (ed). Thyroid cancer. UICC Monograph Series, vol 12. Springer Verlag, Berlin Heidelberg New York p 293Google Scholar
  45. Poston GJ, Thomas H, MacDonald DW, Lynn JA, Lavender JP (1985) 13II-MIBG uptake by medullary carcinoma of the thyroid. Lancet ii:560Google Scholar
  46. Potsaid M, Irwin F, Castronovo G, Prout G, Harvey W, Francis M, Tofe A (1976) Phophorus-32 EHDP clinical study of patients with prostatic carcinoma bone metastases. J Nucl Med 17:548Google Scholar
  47. Robinson R, Spicer JA, Preston DF, Wegst AV, Martin NL (1987) Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 14:219–222Google Scholar
  48. Seeman G, Bosslet K, Sedlacek HA (1987) Human anti-tumour antibodies: problems, opportunities, immunotherapy and scintigraphy of tumours with monoclonal antibodies. Aktuel Onkol 41:21–25Google Scholar
  49. Seidlin SM, Marinelle LD, Oshry E (1946) Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132:838CrossRefGoogle Scholar
  50. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Bierwalters WH (1984) Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterisation. Clin Endocrinol 20:189–203CrossRefGoogle Scholar
  51. Shapiro B, Andrews J, Figg L, Carey J, Walker-Andrews S, Smith J, Ensminger W (1989) Therapeutic intraarterial administration of yttrium-90 glass microspheres for hepatic tumours. Eur J Nucl Med 8:401Google Scholar
  52. Shaw DR, Khazaeli MB, Lobuglio AF (1988) Mouse/human chimeric antibodies to a tumour associated antigen; biological activity of the four human IgG subclasses. J Natl Cancer Inst 80:1553–1559PubMedCrossRefGoogle Scholar
  53. Stewart JSW, Griffiths M, Munro AJ, Lambert JO, Coutter C, Epenetos A (1987) Intraperitoneal radioimmunotherapy for ovarian cancer. Aktuel Onkol 41:65–73Google Scholar
  54. Todd P, Wood JCS, Walker JT, Weiss St J (1985) Lethal, potential lethal and non-lethal damage induction by heavy ions in cultured human cells. Radiat Res 104:S5–S12CrossRefGoogle Scholar
  55. Tubiana M, Lacour T, Marnier J, Bergiron C, Gerard Marchant R, Roujean J, Bok B, Parmentier C (1975) External radiotherapy and radio-iodine in the treatment of 359 thyroid cancers. Br J Radiol 49:894–907CrossRefGoogle Scholar
  56. Van Gils APG, Van Der May AGL, Hoogma RPJM, Falke TITM, Moolenaar AJ, Pauwels EKJ, Van Kroonen Burgh MJPG (1989) Iodium-123 MIBG scintigrafie bij chemodactomen een oprallend resultaat. Nucl Geneeskd Bull 11:61Google Scholar
  57. Wieland DM, Brown LE, Mangner TJ, Swanscombe DP, Bierwaters W (1980) Radiolabeled adrenergic neuro blocking agents: Adreno-medullary imaging with 131I-iodobenzylguanidine. J Nucl Med 21:349–353PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1991

Authors and Affiliations

  • Susan E. M. Clarke

There are no affiliations available

Personalised recommendations